ArticleJournal of early hearing detection and intervention2024
Hyperbilirubinemia Requiring Exchange Transfusion as a Risk Factor for Later-Onset Hearing Loss.
Article in Journal of early hearing detection and intervention, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Previous position statements by the Joint Committee on Infant Hearing (JCIH) have recommended the presence of hyperbilirubinemia requiring exchange transfusion as a risk factor for childhood hearing loss. This article examines the strength of the evidence to support this recommendation. Methods: A PubMed Results: A moderate level of evidence supports hyperbilirubinemia requiring exchange transfusion as a risk factor for elevated hearing thresholds among infants and young children. It is recommended to employ Automated Auditory Brainstem Response screening in this population of infants. These recommendations are based on the findings across multiple graded studies where the net benefit is moderate or substantial. Intervals for on-going monitoring of hearing previously recommended by JCIH are supported by expert consensus. Conclusion: If an infant with hyperbilirubinemia requiring exchange transfusion passes the newborn hearing screening, close monitoring of hearing, speech, and language milestones are important and should lead to improved outcomes for the child.
Indexed as
Identifiers
40034216PMC11875398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.